mnl168 website philippines

mnl168 website philippines

NoneRico Carty, who won the 1970 NL batting title with the Atlanta Braves, dies at 85Deion Sanders and the Colorado Buffaloes wrapped up a successful regular season on Friday with a 52-0 blowout win over Oklahoma State. Sitting at 9-3, the Buffs spent Saturday awaiting a potential spot in the Big 12 title game. Amid some chaotic finishes on Saturday, a notable coaching shakeup in the state of Florida has some wondering whether it could impact Sanders' coaching future in college football. ESPN's Pete Thamel first reported that UCF head coach Gus Malzahn has resigned from his position to join Florida State's coaching staff heading into 2025. According to Thamel, Malzahn will now serve as FSU's offensive coordinator and primary play caller. That duty was previously held by current Florida State head coach Mike Norvell. Norvell fired both his offensive and defensive coordinators on Nov. 10 after a 52-3 blowout loss to Notre Dame. © Mark J. Rebilas-Imagn Images Sanders, who played for FSU from 1985-88 before going on to have a Hall of Fame NFL career, has long been connected by fans and media to the Florida State job since his time leading Jackson State. The 57-year-old has repeatedly stated that he's content at Colorado, and as recently as November following speculation connecting him to one of his former teams, the Dallas Cowboys. Much could still change as the 2024 season wraps up, but Malzahn's move makes it even more unlikely Sanders will be patrolling the FSU sidelines anytime soon. "I'm happy where I am, man," told reporters on Nov. 19. "I've got a kickstand down. You know what a kickstand is? ... That means I'm resting. I'm good, I'm happy, I'm excited. I'm enthusiastic about where I am. I love it here, truly do." “I got a kickstand down...I’m happy, I’m excited, I’m enthusiastic about where I am. I love it here." - Deion Sanders when asked about his name being brought up in conversations about other jobs pic.twitter.com/mHKYK9N5wN Plus, Colorado recently landed five-star quarterback recruit Julian "JuJu" Lewis to replace Deion's son Shedeur Sanders, who will enter the 2025 NFL draft as a likely first-round pick . Florida State proved to be one of the best teams in college football a year ago with a 13-1 record after a loss in the Orange Bowl. Still, Norvell, currently in his fifth season at the helm, has been under fire all season long. The 2-9 Seminoles have played to their worst record since 1974 when the school went 1-10 under then-head coach Darrell Mudra. Muddying the waters, though, is Norvell's bloated contract. The 43-year-old signed an eight-year, $80 million extension in the offseason, making him the sixth-highest paid coach in the sport. As of Nov. 15, his buyout — if FSU wanted to move on in order to make a new hire — would be $61.4 million, according to USA Today . Related: Deion Sanders Earns Huge Bonus After Colorado-Oklahoma State Blowout Related: Terrell Owens Gets Brutally Honest on Controversial Travis Hunter DecisionSAN DIEGO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of The Toronto-Dominion Bank ("TD Bank") TD securities between February 29, 2024 and October 9, 2024, both dates inclusive (the "Class Period"), have until Monday, December 23, 2024 to seek appointment as lead plaintiff of the TD Bank class action lawsuit. Captioned Tiessen v. The Toronto-Dominion Bank , No. 24-cv-08032 (S.D.N.Y.), the TD Bank class action lawsuit charges TD Bank and certain of TD Bank's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the TD Bank class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-the-toronto-dominion-bank-class-action-lawsuit-td.html You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com . CASE ALLEGATIONS : The Toronto-Dominion Bank offers its products and services in the United States under the "TD Bank" and "America's Most Convenient Bank" brand names. The TD Bank class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts concerning the true state of TD Bank's anti-money laundering ("AML") program; pertinently, TD Bank concealed or otherwise minimized the significance of the failures of TD Bank's AML program and made no indication that the imposition of an asset cap or other punitive or compliance measures would be imposed that would undermine TD Bank's continued growth for the foreseeable future. The TD Bank class action lawsuit further alleges that, on October 10, 2024, TD Bank unveiled the resolutions reached from U.S. investigations, which included, in addition to the punitive payment of $3.09 billion, both an asset cap, preventing TD Bank's U.S. subsidiaries from exceeding a collective $434 billion, a reflection of TD Bank's assets as of September 30, 2024, and further subjects TD Bank to more stringent approval processes for its product, service, and market rollouts. Further, the U.S. Department of Justice, in their own corresponding release, highlighted the significance of TD Bank's failures as "the largest bank in U.S. history to plead guilty to Bank Secrecy Act program failures and the first U.S. bank in history to plead guilty to conspiracy to commit money laundering," the complaint alleges. On this news, TD Bank's stock price fell by more than 10%, according to the TD Bank class action lawsuit. THE LEAD PLAINTIFF PROCESS : The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired TD Bank securities during the Class Period to seek appointment as lead plaintiff in the TD Bank class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the TD Bank class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the TD Bank class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the TD Bank class action lawsuit. ABOUT ROBBINS GELLER : Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities-fraud.html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@rgrdlaw.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Andrew Hammond Christmas holidays tend to be a time of joy for many families around the world. However, this year’s festivities will also be tinged with great sadness for many as the world on Thursday (Dec. 26) marks the 20th anniversary of the devastating Boxing Day Tsunami. Two decades on from the deadly waves, caused by a massive earthquake, that caused devastation in countries with Indian Ocean coastlines, scientific advances have improved our ability to forecast and provide warnings of dangerous tsunamis. However, the economic and wider human costs of such natural catastrophes can never be completely eliminated. This was illustrated, for example, by the concern caused by a magnitude 7.0 earthquake this month about 55 miles off the coast of Eureka in California. The effects were felt from San Francisco to southern Oregon, sparking a tsunami warning affecting millions of residents. The alert was later canceled. Tsunami warnings are relatively rare on the US West Coast but still more common than elsewhere in the country. However, some scientists predict the area might be overdue for a massive quake, and resulting tsunami, in the Cascadia Subduction Zone, an 1,100 km offshore fault that runs from northern California to southern British Columbia, and/or the San Andreas fault, which runs for 1,200 km through California. Some scientists refer to this potentially huge natural disaster as “The Big One,” defined as an earthquake of magnitude 8.0 or higher on the Richter scale. Such an event could cause hundreds of billions of dollars of damage, and tens of thousands of deaths and injuries at the very least. But even a disaster of that magnitude might still be dwarfed by the devastation caused by the 2004 Boxing Day Tsunami in the Indian Ocean. According to the EM-DAT global disaster database, it killed a total of 226,408 people in more than a dozen countries, and more than 1.5 million people were displaced. The magnitude 9.1 earthquake that caused the tsunami was one of the biggest the world had seen since 1900. The epicenter was off the western coast of the Indonesian island of Sumatra. It was the longest fault line rupture ever observed, as the ocean floor opened up along a distance of at least 1,200 km between the India plate and Burma microplate. The earthquake triggered the largest tsunami in the Indian Ocean for more than 700 years. The amount of energy it released was estimated to be equivalent to about 23,000 Hiroshima bombs. The huge waves it created, some more than 30 meters high, swept into several coastal nations, including Indonesia, Sri Lanka, India and Thailand. Twenty years on, the silver lining amid the sadness of the upcoming anniversary is that our understanding of tsunami risks is now better. This means better forecasting, more effective warnings, and improved disaster-resistant construction techniques for more-resilient infrastructure. In terms of warning systems, there were none in place in the Indian Ocean region in 2004. The picture has changed since then, with a regional system in place as part of an approximately 1,400-strong network around the world that generally reduces the delay in issuing a warning after a tsunami forms to just minutes. Even with such improved warning systems, some communities still might not receive the alert in time. Indeed, had the present-day Indian Ocean warning system been in place in 2004, it is not certain it would have helped many of those among the first hit by the tsunami, especially in poorer communities lacking the benefit of modern digital technologies. In part, this is why a significant proportion of tsunami casualties tend to happen before any official or technically based warnings can be delivered. This differs from some other natural hazards, such as hurricanes, which can be predicted further in advance and tend to cause fewer casualties. However, for people more distant from the origin point of a tsunami, warnings can be very effective, including those transmitted through community communications. These can save many lives, with a key factor in success being the distribution of data rapidly, transparently, and hyper-locally, so that it is available in the best form, in the right place and as quickly as possible. As warning systems improve, there are continuing debates about the enhanced exchange of data. This places an increasing amount of weight on improved forecasts. Such methods of predicting earthquakes in advance were once thought to be impossible, owing to the difficulty of calculating the motion of rocky mantle flows beneath the earth’s crust. Thanks to increasingly sophisticated algorithms, however, it might now be possible to model this underground activity in more effective ways by creating a model of fault lines, consisting of millions of underground grid points, to ascertain where the underground stresses are strongest. This is a potential indicator of key earthquake trigger points. However, even if forecasting technology and early warnings can fulfill their full longer-term potential, there is still a need for increasingly resilient infrastructure, given the devastation tsunamis can cause to physical geography. Take the example of the province of Aceh in Indonesia, one of the areas worst-hit by the 2004 tsunami. Hundreds of thousands of homes were destroyed and about 3,000 hectares of land were washed away, destroying infrastructure such as roads, ports, and bridges. More than 100,000 houses have been rebuilt there, according to the Indonesian government. In this context, a key goal for engineers and community planners is to build increasingly tsunami-proof structures and plan more-resilient communities. As global warming intensifies, these calculations must also factor in the growing risk from rising sea levels, a threat that is increasing three times faster in tropical seas — including central portions of the Pacific and Atlantic Oceans and much of the Indian Ocean — where tsunami risks tend to be greatest. All of this underlines the further potential for improved forecasting and earlier warnings of future tsunamis to help make the world a safer place for many people. However, the economic and wider human cost of such terrifying natural hazards can never be eliminated, even with increasingly resilient infrastructure. Courtesy: arabnewsNoneApple might be working on a smart doorbellUS News Today Live Updates on December 24, 2024 : Denzel Washington takes the big leap into faith, gets baptized: 'It took a while but I'm here'

Supermarket shopping can be a chore at the best of times, but at Christmas it can take on a whole new level of inconvenience, with queues, inflated prices and items out of stock. So, it pays to know when your particular store might be quietest, when staff will have restocked the shelves and when items get marked down for the best yellow sticker bargains. With nearly 30% of Brits admitting Christmas food shopping is their holiday nightmare, Britsuperstore has analysed the UK's top 10 supermarket chains to find the perfect times to do your Christmas shopping at each one. Top 10 Supermarkets: Aldi Busiest: Monday-Friday 5-6pm, Saturday 12pm, Sunday 3pm Quietest: Monday-Friday 8-9am and 9-10pm, Saturday 8-9am and 9-10pm, Sunday 11am Restock: Before opening and 3pm (Special Buys every Thursday and Sunday) Reductions: Before 8am and before closing (fresh produce with red stickers typically discounted 30-75%) The exact time of day for reductions will vary from store to store, but most will happen just before the store closes. Fresh products with reduced prices will be marked by a red sticker, and are typically reduced as they are at the end of their shelf life. They will normally be discounted by either 30% or 75%. Dried groceries and tinned food may also be discounted if they have imperfections. Recommended reading: DWP Christmas bonus to be paid to people on these benefits Savings accounts: best and worst for savings interest Housing benefit payments to be frozen next year Lidl Busiest: Monday-Friday 12-1pm and 5-6pm, Saturday 12-3pm, Sunday 12pm Quietest: Monday-Friday 8am and 10-11pm, Saturday 8am and 10-11pm, Sunday 4-5pm Restock: Late night and overnight Reduction: Morning and before closing (they have a two-wave reduction system, first thing in the morning and a few hours before closing) Again, the schedule for price reductions varies from store to store, but the majority of branches operate on a two-wave basis. Products are reduced first thing in the morning and a few hours before the store closes, although some stores may opt to make reductions throughout the day based on the volume of stock and sell-by dates. Morrisons Busiest: Monday-Friday 12-1pm, Saturday 1pm, Sunday 12pm Quietest: Monday-Friday 7-9am and 9-11 pm, Saturday 7-8am and 9-11pm, Sunday 4pm Restock: 5-6pm Reduction: Starts at 3pm (50% off for near-expiry items), followed by a further reduction at 5pm (75% off) with final dramatic reductions on in-store cooked food at 8pm (schedule may vary) Morrison stores typically have several waves of price reductions. Reductions begin at 3pm, with products at the end of their shelf life reduced by 50%. At 5pm, these products are reduced again, retailing at 75% of their original price. If you’re looking for a bargain on in-store cooked food, we recommend visiting the store at 8pm, as items will be dramatically reduced. Remember, the schedule for reductions may vary depending on the branch. The Co-Operative Busiest: Monday-Friday 5-6pm, Saturday 6pm, Sunday 5-6pm Quietest: Monday-Friday 7am and 9-10pm, Saturday 7-8am and 9-10pm, Sunday 7-8am and 9-10pm Restock: Mostly overnight Reduction: Starts around 6pm (50% off for expiry-date items), with a possible further reduction at 8pm (schedule may vary) Visit your local Co-op at around 6pm to be sure of a discount, although, at some stores, reductions start at 5pm. Items on sale on the day of their expiration date will usually be sold at 50% of their original price Tesco Busiest: Monday-Friday 3-6pm, Saturday 12-2pm, Sunday 12pm Quietest: Monday-Friday 7am and 8-11pm, Saturday 7-9am and 9-11pm, Sunday 7-8am and 10-11pm Restock: 6:30 AM Reduction: Starts at 9am (around 10% off), with further reductions between 4-5pm (around 30% off). Best reductions around 8pm (schedule may vary) At around 9am, items are reduced by around 10%. Some products are reduced further between 4pm and 5pm, by about 30%. For the best reductions, visit about 8pm, but again, keep in mind discount schedule may vary by store. Sainsbury's Busiest: Monday-Friday 12-4pm, Saturday12 pm, Sunday 3pm Quietest: Monday-Friday 7-9am and 7-10 pm, Saturday 8-9am and 9pm, Sunday 11pm and 4pm Restock: When closed and throughout the day Reduction: Starts after lunch (biggest discounts between 5-7pm) with significant variations by store (check with your local store) Reduction times at Sainsbury’s varies significantly by store. Make sure to visit after lunch, as this is when most stores begin to reduce their products. The best time to visit is between 5 pm and 7 pm, as this is when the biggest discounts will happen. ASDA (24 hours) Busiest: Monday-Friday 5-6pm, Saturday 1pm, Sunday 12pm Quietest: Monday 6-8am and 10-2pm, Tuesday-Friday 10pm-7am, Saturday 12-7am, Sunday 11am and 4pm Restock: 10 pm Reduction: Early morning (6-10am), 5pm, and 7:30pm (schedule may vary) Reductions at ASDA typically begin between 6 am and 10 am. There is a second round of reductions takes place at about 5 pm, and final reductions begin at around 7:30 pm. Again, discount schedules may vary from store to store. M&S Busiest: Monday-Friday 5-6pm, Saturday 4pm, Sunday 1-3pm Quietest: Monday-Friday 8am and 8-9pm, Saturday 8-9am and 6-7pm, Sunday 5-6pm Restock: 7 am Reduction: Around 9am (10% off), 2pm (30% off), and after 4pm (70-90% off) At most Marks & Spencer stores, there are three waves of reductions. The first wave takes place around 9 am, where some items may be reduced by 10%. The real reductions, however, begin around 2 pm. Here, products are normally reduced by 30%. The final wave of reductions happens after 4 pm, where products are reduced between 70% and 90%. Waitrose Busiest : Monday-Friday 6-7 pm, Saturday 6 pm, Sunday 4 pm Quietest: Monday-Friday 8-9am and 9-10pm, Saturday 8-9am and 9-10pm, Sunday 12pm Restock: 11am Reduction: Two hours before closing (around 50% off fresh food) The majority of Waitrose branches begin to reduce their products just after the lunchtime rush. For the best shot at reduced items at the best price, however, we recommend visiting stores two hours before closing time, when some stock, and in particular fresh food, is reduced by around 50%. Iceland Busiest: Monday-Friday 5pm, Saturday 1pm, Sunday 1pm Quietest: Monday-Friday 8-9am, Saturday 8-9am, Sunday 10am Restock: Before opening Reduction: Added to deliveries, plus flash discounts and schemes (check local store) At Iceland, reductions are added to deliveries. Iceland also offers “flash discounts”, and discount schemes, so be on the lookout for these. Last year, for example, they announced a scheme which allowed customers over the age of 60 to get 10% off their groceries with no minimum spend every Tuesday. Remember: Reduction schedules may vary by store for every chain, so always check with your local branch. Seven expert Christmas food shopping hacks Richard Price, Director of Britsuperstore , an online supermarket which specialises in food for expats, shares his seven tips to save this Christmas. Shop online to avoid queues and see what's in stock. Use budget shops like Home Bargains, Poundland, B&M, Lidl, and Aldi for good value food and own-brand spirits. Bulk buy and check prices per kilogram and consider warehouse clubs like Costco or Food Warehouse. Set a budget, make a list, and avoid impulse buys. Substitute national brands with store brands to save up to 30%. Don't just shop at eye level make sure to look above and below for better deals. Plan ahead and aim to finish your shopping by December 22 to beat the last-minute rush.Emergency services at scene of serious crash on Glenshane Pass

‘Always really wary’: Socceroos star’s ‘frustrating’ injury blow in striker’s nervous waitCommerce Bank Raises Stock Position in Delta Air Lines, Inc. (NYSE:DAL)Rico Carty, who won the 1970 NL batting title with the Atlanta Braves, dies at 85Luke Littler falls to familiar foe as darts superstar loses Players' Championship Final

MENLO PARK, Calif. , Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA , on January 14, 2025 . BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years. This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows: Location: Mission Bay (32nd Floor) at The Westin Date: Tuesday, January 14, 2025 Time: 2:30-2:55 pm PT A webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/ About BillionToOne Headquartered in Menlo Park, California , BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone. The company's patented Quantitative Counting TechnologyTM (QCTTM) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, please visit www.billiontoone.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/billiontoone-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302338634.html SOURCE BillionToOne

Inquirer photo MANILA, Philippines — The Sandiganbayan has junked two of the eight ill-gotten wealth cases against the late President Ferdinand Marcos Sr., his wife Imelda, and the late tycoon Eduardo Cojuangco Jr., over the alleged anomalous purchase of a controlling stake in United Coconut Planters Bank (UCPB) as well as the acquisition of San Miguel Corp. (SMC) shares using the controversial coconut levy funds. In dismissing the civil cases, the antigraft court’s Second Division cited in its Dec. 6 resolution the motion of the Presidential Commission on Good Government (PCGG), represented by the Office of the Solicitor General (OSG), to waive its claim for civil damages that it earlier sought. The court referred to the government’s manifestation and motion as well as a PCGG resolution dated July 15, 2024, which states that “the commission will no longer pursue its claim for the actual, moral, temperate, nominal and exemplary damages... as the subject of the said cases, and to initiate legal proceedings to facilitate the transfer of UCPB shares in Cocolife to the Republic of the Philippines.” The PCGG is the agency created in 1986 under the Cory Aquino administration, following the downfall of the Marcos regime, to go after the ill-gotten assets of the late dictator, his immediate family, relatives and cronies. The two junked cases were among the legal remedies it sought for the recovery of Marcos’ assets, coming to a close after almost three decades and with Ferdinand Sr.’s son and namesake as the country’s President. Civil Case No. 0033-A, which was filed by the OSG in March 1995 in connection with the alleged anomalous purchase and use of the First United Bank (FUB), the predecessor of UCPB, and Civil Case No. 0033-F, which was filed in May 1995 over the “unlawful use” of coco levy funds to buy SMC shares. Cojuangco was alleged to have “coveted the coconut levy funds as a cheap, lucrative and risk-free source of funds with which to exercise his private option to buy controlling interest in the FUB” at 72.2 percent of the outstanding capital stock. He also supposedly bought a block of 33,133,266 shares of SMC stock through a group of 14 holding companies owned by six oil mills. Cojuangco served as the president and CEO of UCPB and was named the administrator of the coco levy fund. UCPB, on the other hand, was also tasked to handle the Coconut Industry Investment Fund (CIIF), which covers 14 holding firms under six oil mills. Then President Marcos imposed a levy from coconut farmers from 1972 to 1982 supposedly to improve the state of the country’s coconut industry and he also greenlighted in 1975 the use of coco levy funds to buy FUB purportedly “for the benefit of farmers.” In its 33-page resolution, the Sandiganbayan said that the government’s motion and manifestation must be granted as it “has the effect and import of a motion to withdraw under Sec. 2, Rule 17 of the Rules of the Court.” The PCGG pointed to the earlier Supreme Court rulings in Cocofed, et al. v. Republic; and Cojuangco v. Republic; which both resolved with finality the cases and affirmed the Sandiganbayan’s partial summary judgments declaring the SMC shares under the CIIF block and UCPB shares covered by the cases as being rightfully owned by the government. These shares were then ordered reconveyed to the government “to be used only for the benefit of all coconut farmers.” The court added: “Furthermore, the PCGG itself intimated its belief that [the] civil cases... have both been disposed of with finality by the Supreme Court and the only matter that remains for resolution is the complaint-in-intervention filed by Subic International Air in Civil Case No. 0033-A.” The representatives of the defendants, namely the Marcos couple and Cojuangco, did not object to the government’s motion to revoke the pursuit of the damages in the civil cases. Due to the pending motion for intervention by Subic Air, the antigraft court ruled that the civil case in connection with the purchase of UCPB will “remain active” as a compromise deal between the government and the aviation firm is still ongoing. The PCGG also asked for more time to reach a settlement. In its motion filed in 2004, Subic Air alleged that one of its aircraft, a Gates Learjet Model 35-A, was “erroneously sequestered” in the case as the company had a “mechanic’s lien” on it. “An intervenor has the right to claim the benefit of the original suit and to prosecute it to judgment. The right cannot be defeated by the dismissal of the suit by the plaintiff,” the court said. “In the interest of substantial justice, the court shall allow the parties the opportunity to amicably settle Subic Air’s intervention.” Meanwhile, the Sandiganbayan rendered moot and academic the motion to dismiss filed by Juan Ponce Enrile, who was also a respondent in six ill-gotten wealth cases, citing the earlier dismissal of the cases. Enrile, who is most known for his role as defense minister during the administration of the elder Marcos, now serves as a legal counsel for Marcos’ namesake and son. The high tribunal had also earlier granted Cojuangco’s petition for prohibition, effectively throwing out the six other civil cases pertaining to alleged ill-gotten wealth of the Marcoses and their supposed cronies due to violation of their right to a speedy disposition of cases. The 2021 ruling was handed down nearly a year after the death of Cojuangco in June 2020. Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . The other six subdivided cases docketed in the Sandiganbayan were Civil Case No. 0033-B, or the alleged creation of companies out of coco levy funds; Civil Case 0033-C, or the alleged creation and operation of the Bugsuk project and award of P998 million in damages to agricultural investors; Civil Case 0033-E, or the alleged unlawful disbursement and dissipation of coco levy funds; Civil Case 0033-G, or the acquisition of Pepsi-Cola; and Civil Case 0033-H, or the alleged behest loans and contracts.NEW YORK , Dec. 10, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global alzheimer's disease therapeutics market size is estimated to grow by USD 5.41 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.03% during the forecast period. Availability, research, and development of novel biomarkers is driving market growth, with a trend towards emergence of regenerative therapies. However, high cost of therapeutics development poses a challenge. Key market players include AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth Alzheimer's disease, a leading cause of dementia among older adults, continues to be a major health concern. According to NCBI, over 6 million Americans are diagnosed with Alzheimer's and related dementias, leading to significant disability and increased deaths. The Alzheimer's disease therapeutics market is witnessing advancements in treatment with the introduction of drug classes like cholinesterase inhibitors (Aricept, Exelon, Razadyne) and Amyloid beta inhibitors (Crenezumab). Biological therapies, such as Tau antibody, are also in the pipeline. Cognitive assessment systems and smartphones aid in early diagnosis. Distribution channels, including hospitals, hospital pharmacies, online pharmacies, and e-commerce platforms, facilitate access to these drugs. Men and women, especially Medicare beneficiaries, are the primary consumers. Memantine, another drug class, targets memory impairment and thinking skills. Life expectancy and disability are significant factors driving market growth. Everyday tasks and social skills are also affected, making these therapies essential. Drug discovery techniques continue to evolve, increasing the prescription rate. Alzheimer's disease is a significant health concern for the elderly population, characterized by memory loss and cognitive decline. The disease is marked by the presence of amyloid B-peptide plaques and tau neurofibrillary tangles. Despite extensive research, no disease-modifying treatments have been discovered. Neuronal death, synaptic failure, dendritic and axonal atrophy are some of the disease's progressive symptoms. Researchers continue their efforts to find curative therapies, focusing on understanding the underlying mechanisms of neuronal damage and cognitive impairment. The Alzheimer's disease therapeutics market is currently in search of effective treatments to address this unmet medical need. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! • Alzheimer's disease, a leading cause of dementia, affects over 6 million Americans, with numbers projected to triple by 2050. The Alzheimer's disease therapeutics market faces challenges in advancing treatment, with current options including cholinesterase inhibitors like Aricept and Exelon, and NMDA receptor antagonist Memantine. Amyloid beta inhibitors, such as Crenezumab, are in the pipeline. Behavioral skills and thinking impairments impact everyday tasks, leading to disability and increased healthcare costs for diagnosed patients. Biological therapies, like Tau antibody, show promise. Distribution channels, including hospitals, hospital pharmacies, e-commerce platforms, and online pharmacies, aim to improve access. Drug discovery techniques and cognitive assessment systems aid diagnosis among Medicare beneficiaries, mostly women. Life expectancy and memory impairment drive high prescription rates. Smartphones and the Internet facilitate access to e-commerce services, enabling easier access to these essential medications. • The Alzheimer's disease therapeutics market is significant due to the growing number of patients requiring symptomatic relief. Currently, available treatments only manage the symptoms of the disease. The pressing need for disease-modifying therapeutics arises from the increasing prevalence of Alzheimer's disease. Researchers are actively working on developing such treatments, but the high development costs and challenges in clinical trials pose obstacles to market expansion. The estimated cost of an Alzheimer's disease therapeutics development program is approximately USD5.6 billion , and the process takes around 13 years, from preclinical studies to US FDA approval. Insights into how AI is reshaping industries and driving growth- Download a Sample Report This alzheimer's disease therapeutics market report extensively covers market segmentation by 1.1 Hospital pharmacy 1.2 Retail pharmacy 1.3 E-commerce pharmacy 2.1 Cholinesterase inhibitors 2.2 N-methyl-D-aspartate receptor antagonist 2.3 Others 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Hospital pharmacy- The hospital pharmacy segment of the Alzheimer's disease therapeutics market is experiencing significant growth due to the large-scale demand for these drugs in hospitals. This trend is driven by several factors, including increasing government investments in healthcare infrastructure in countries like India and China , the expansion of hospital facilities in developing nations, and the rising number of Alzheimer's disease cases worldwide. As a result, hospitals are becoming major distribution channels for Alzheimer's disease therapeutics. These factors collectively are expected to boost the growth of the hospital segment of the Alzheimer's disease therapeutics market during the forecast period. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) The Alzheimer's disease therapeutics market encompasses innovative treatments for neurodegenerative diseases, primarily Alzheimer's and dementias. Two major categories include Amyloid beta inhibitors and biological therapies. These treatments aim to slow down the progression of these conditions by targeting the buildup of beta-amyloid plaques and tau tangles in the brain. Both men and women are affected, with women making up two-thirds of the estimated 5.8 million Americans living with Alzheimer's disease. Life expectancy plays a significant role, as the majority of Medicare beneficiaries, who are aged 65 and above, are at increased risk. The prescription rate for these therapies is growing as more clinics and hospitals integrate cognitive assessment systems into their routine patient care. Memory impairment, thinking, behavioral skills, and social skills are common symptoms, affecting everyday tasks and quality of life. Alzheimer's disease, a leading cause of dementia and neurodegenerative diseases, affects memory impairment, thinking, and social skills in older adults. The Alzheimer's disease therapeutics market is witnessing significant advancements in treatment with the development of various drug classes, including cholinesterase inhibitors (Aricept, Exelon, Razadyne) and Amyloid beta inhibitors (Crenezumab). Biological therapies, such as Tau antibody, are also under investigation. Cognitive assessment systems aid in diagnosis, while distribution channels, including hospitals, hospital pharmacies, online pharmacies, and e-commerce platforms, facilitate access to these essential medications. With an increasing number of diagnosed patients, particularly among older adults, life expectancy, and Medicare beneficiaries, the prescription rate for Alzheimer's disease therapeutics continues to rise. The use of drug discovery techniques and technological advancements, such as smartphones and the Internet, are revolutionizing the way these therapies are administered and monitored. Despite these advancements, Alzheimer's disease remains a significant cause of disability and deaths, with a disproportionate impact on Men and Women. The pipeline drugs offer hope for future treatments, aiming to slow down the progression of the disease and improve the quality of life for those affected. 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Distribution Channel Hospital Pharmacy Retail Pharmacy E-commerce Pharmacy Drug Class Cholinesterase Inhibitors N-methyl-D-aspartate Receptor Antagonist Others Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio